The pharmaceutical and biological sector has been heavily sold off by the main funds in the past three days

Clinical CRO Tigermed: The ‘Small and Beautiful’

In this race of pharmaceutical R&D outsourcing segment, WuXi AppTec, Pharmaron, Tigermed and Asychem are some of the major names – but which has a truly winning side?

Chinese technology enterprise Dreame (追觅科技) reports eight consecutive years of doubled revenue, leading market share in over 30 countries

On April 20, Yu Hao (俞浩), founder and CEO of Dreame Technology (追觅科技), shared his unique business philosophy in an interview. He revealed that since its founding in 2017, Dreame has achieved an average annual revenue growth of 100% for eight consecutive years. By the end of 2025, Dreame’s products reached 120 countries and regions, securing the No. 1 market share in the robotic vacuum segment across more than 30 countries, including Germany, Italy, and Singapore.

CRO ClinChoice Raises USD 150 Mn in Series E Round

2015 is the inflection point for the development of China's innovative drug industry and CRO (clinical research organization). On July 22nd, 2015, after CDE (Center For Drug Evaluation) released the announcement on self-examination and verification of drug clinical trial data, the supervision of Chinese clinical trials moved towards standardization. The investment and financing of innovative drugs in China continued to increase, laying the foundation for the growth of CRO.

CRO Giant Tigermed’s 1H 2020 Net Profits Up 98%

Chinese CRO industry is setting off – the continued pandemic may bring the most potential to this industry.

WuXi AppTec: A Favorable Chinese Stock for MSCI and FTSE Russell

According to the latest quarterly index review, a Wuxi-based CRO company will be incorporated into the FTSE China A 50 Share Index.  It has been considered a top holding by many MSCI China indexes for some time.